Multiple sclerosis future or investigational therapies
|
Multiple sclerosis Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Multiple sclerosis future or investigational therapies On the Web |
|
American Roentgen Ray Society Images of Multiple sclerosis future or investigational therapies |
|
FDA on Multiple sclerosis future or investigational therapies |
|
CDC on Multiple sclerosis future or investigational therapies |
|
Multiple sclerosis future or investigational therapies in the news |
|
Blogs on Multiple sclerosis future or investigational therapies |
|
Risk calculators and risk factors for Multiple sclerosis future or investigational therapies |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Future or investigational therapies
Diagnostic studies under investigation
A test, which may become important in the future to diagnose multiple sclerosis, is measurement of antibodies against myelin proteins such as myelin oligodendrocyte glycoprotein (MOG) and myelin basic protein (MBP). As of 2007, however, there is no established role for these tests in diagnosing MS. Optical coherence tomography of the eye's retina is also under study[1], mainly as a tool to measure response to medication and axonal degeneration[2].
Therapies under investigation
Scientists continue their extensive efforts to create new and better therapies for MS. There are a number of treatments under investigation that may curtail attacks or improve function. Some of these treatments involve the combination of drugs that are already in use for multiple sclerosis, such as the combination of mitoxantrone and glatiramer acetate (Copaxone).[3] However most treatments already in clinical trials involve drugs that are used in other diseases or medications that have been designed specifically for MS. Finally, there are also many basic investigations that try to understand better the disease and in the future may help to find new treatments.
References
- ↑ Gordon-Lipkin E, Chodkowski B, Reich DS; et al. (2007). "Retinal nerve fiber layer is associated with brain atrophy in multiple sclerosis". Neurology. 69 (16): 1603–09. PMID 17938370. Unknown parameter
|month=ignored (help) - ↑ Albrecht P, Fröhlich R, Hartung HP, Kieseier BC, Methner A (2007). "Optical coherence tomography measures axonal loss in multiple sclerosis independently of optic neuritis". J Neurol. Online. doi:10.1007/s00415-007-0538-3. PMID 17987252.
- ↑ United Kingdom early Mitoxantrone Copaxone trial. Onyx Healthcare (2006-01-01). Retrieved on2007-09-02.